Invidior’s Opvee Opioid Overdose Nasal Spray Gets FDA Approval

The FDA has approved Invidior’s Opvee drug-device combination nasal spray for emergency treatment of opioid overdose in adult and pediatric patients ages 12 and older.

The spray dispenses nalmefene, an opiod receptor that begins reversal of opioid-induced respiratory depression within 2.5 to 5 minutes, with full recovery of respiratory drive as early as five minutes after administration.

The company expects to market the product in Q4 2023.

Related Topics